Literature DB >> 16080460

Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.

Dominique Levêque1, Sandra Wisniewski, François Jehl.   

Abstract

This review presents the clinical pharmacokinetics of the marketed therapeutic monoclonal antibodies used in oncology. Aspects regarding absorption, tissue distribution, elimination as well as factors influencing pharmacokinetics, pharmacodynamics and kinetic interactions are also discussed.

Mesh：

Substances：

Year:  2005        PMID： 16080460

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  22 in total

Review 1.  Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab.

Authors:  Bing-Bing Yang; Peggy Lum; Alin Chen; Rosalin Arends; Lorin Roskos; Brian Smith; Juan José Pérez Ruixo
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.

Authors:  Seth Hetherington; Michele Texter; Eric Wenzel; Joseph M Patti; Laurie Reynolds; Trish Shamp; Suzanne Swan
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

3.  Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.

Authors:  Tianjiao Duan; Lukmanee Tradtrantip; Puay-Wah Phuan; Jeffrey L Bennett; Alan S Verkman
Journal:  Neuropharmacology       Date:  2019-10-22       Impact factor: 5.250

Review 4.  Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.

Authors:  Xing Jing; Yan Hou; William Hallett; Chandrahas G Sahajwalla; Ping Ji
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 5.  Targeted drug delivery for cancer therapy: the other side of antibodies.

Authors:  Michael A Firer; Gary Gellerman
Journal:  J Hematol Oncol       Date:  2012-11-09       Impact factor: 17.388

6.  Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.

Authors:  Martin J Hicks; Kosuke Funato; Lan Wang; Eric Aronowitz; Jonathan P Dyke; Douglas J Ballon; David F Havlicek; Esther Z Frenk; Bishnu P De; Maria J Chiuchiolo; Dolan Sondhi; Neil R Hackett; Stephen M Kaminsky; Viviane Tabar; Ronald G Crystal
Journal:  Cancer Gene Ther       Date:  2014-12-12       Impact factor: 5.987

Review 7.  Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.

Authors:  Jonathan De Siqueira; Izma Abdul Zani; David A Russell; Stephen B Wheatcroft; Sreenivasan Ponnambalam; Shervanthi Homer-Vanniasinkam
Journal:  J Cardiovasc Transl Res       Date:  2015-09-18       Impact factor: 4.132

8.  Bevacizumab for the treatment of glioblastoma.

Authors:  Miguel J Gil-Gil; Carlos Mesia; Montserrat Rey; Jordi Bruna
Journal:  Clin Med Insights Oncol       Date:  2013-06-06

9.  A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletion.

Authors:  Felix Scheuplein; Abraham Thariath; Susan Macdonald; Alemseged Truneh; Robert Mashal; Robert Schaub
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies.

Authors:  Boris Grinshpun; Nels Thorsteinson; Joao Ns Pereira; Friedrich Rippmann; David Nannemann; Vanita D Sood; Yves Fomekong Nanfack
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.